New immune cell therapy tracks itself in the body to fight lymphoma
NCT ID NCT07343934
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tests a new type of cell therapy for people with follicular lymphoma that has come back or not responded to at least two prior treatments. The therapy uses a patient's own immune cells, modified to target cancer cells and also carry a tracking tag that can be seen on PET scans. Only 6 participants will be enrolled to check safety and whether the tracking method works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
genetically modified immune cells (huCART19-IL18-eDHFR)
What this could lead to
If it works, this could point toward a new treatment option for people with follicular lymphoma that has stopped responding to standard therapies.
What could go wrong
This is a very early phase 1 trial with only 6 participants, so it is too small to prove effectiveness. The main goal is safety and imaging, not treatment benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••